ストックスクリーナーアプリを入手
8.24
0.00%
0.00
前日終値:
$8.24
開ける：
$8.415
24時間の取引高:
8,924
Relative Volume:
0.49
時価総額：
$37.51M
収益：
$85.53M
当期純損益:
$-9.78M
株価収益率:
-3.7536
EPS:
-2.1952
ネットキャッシュフロー:
$1.28M
1週間 パフォーマンス:
-3.06%
1か月 パフォーマンス:
+2.62%
6か月 パフォーマンス:
+91.18%
1年 パフォーマンス:
+96.38%
1日の値動き範囲:
$8.23
$8.53
1週間の範囲:
$7.98
$8.80
52週間の値動き範囲:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
名前
Harvard Bioscience Inc
セクター
電話
(508) 893-8999
住所
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, RMD, MDLN, ALC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
8.24 | 37.51M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
427.64 | 151.08B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.89 | 51.45B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
234.60 | 32.99B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.76 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.35 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 開始されました | Northland Capital | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | ダウングレード | Janney | Buy → Neutral |
| 2018-01-24 | 繰り返されました | Janney | Buy |
| 2018-01-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-11-17 | 開始されました | Singular Research | Buy |
| 2015-07-28 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Harvard Bioscience Inc (HBIO) 最新ニュース
Harvard Bioscience creates scientific advisory board - Investing.com
Harvard Bioscience forms scientific advisory board with four members - StreetInsider
Harvard Bioscience Announces Creation Of Scientific Advisory Board - TradingView
Harvard Bioscience Announces Creation of Scientific Advisory Board - GlobeNewswire
Harvard Bioscience, Inc. Announces Creation of Scientific Advisory Board - www.marketscreener.com
Harvard Bioscience stock gained 1.92 percent on October 5, 2026 - AD HOC NEWS
Harvard Bioscience grows revenue 11.10 percent: what it means for Harvard Bioscience stock - AD HOC NEWS
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Harvard Bioscience stock holds at USD 7.92 after reverse split - AD HOC NEWS
Over 5% stake disclosed in Harvard Bioscience (HBIO) - Stock Titan
Harvard Bioscience stock trades steady as investors look to latest revenue trends - ad-hoc-news.de
Harvard (HBIO) Chart: Records a 0.13% Increase to $7.49; Price Context: the Price Remains Bounded by the Supplied Support and Resistance on the DayVolatility Surface - vinanet.vn
Harvard Bioscience Insider Confidence Rewarded, Stock Hits US$32m Market Cap - Sahm
Harvard Bioscience Insider Confidence Rewarded, Stock Hits US$32m Market Cap - simplywall.st
Harvard (HBIO) Results Review: EPS Exceeds Its Estimate in the Current Update; Session Move: The Stock Gains 1.58% at the CloseNet Profit Margin - vinanet.vn
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript - AOL.ca
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com South Africa
HBIO Maintained by Benchmark -- Price Target Raised to $7.50 - GuruFocus
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com India
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com UK
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Harvard Bioscience, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-08-12 - Seeking Alpha
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary - TradingView
Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs - Stock Titan
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights - GuruFocus
HBIO Looks 66.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ... - Yahoo Finance
Harvard Bioscience Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com Nigeria
HBio Q2 2026 slides: revenue up 11%, China growth drives guidance raise - Investing.com Nigeria
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance - Yahoo Finance
Harvard Bioscience Raises Full-Year 2026 Revenue Guidance After Strong Second-Quarter Growth - Minichart
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com
Why is Harvard Bioscience stock gaining today? By Investing.com - Investing.com Canada
Is Harvard Bioscience Inc (HBIO) Undervalued After Q2 Earnings B - GuruFocus
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com South Africa
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com Australia
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com Canada
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience Announces Second Quarter 2026 Financial Results - The Manila Times
Harvard Bioscience: Q2 Earnings Snapshot - marketscreener.com
Harvard Bioscience: Q2 Earnings Snapshot - AOL.com
Harvard Bioscience: Q2 Earnings Snapshot - KTVB
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook - TradingView
Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million - Quiver Quantitative
Harvard Bioscience Announces Second Quarter 2026 Financial Results - marketscreener.com
Harvard Bioscience Inc (HBIO) 財務データ
収益
当期純利益
現金流量
EPS
Harvard Bioscience Inc (HBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
1.13%
0.57%
大文字化:
|
ボリューム (24 時間):